Ricardo Andreotti Siqueira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ricardo Andreotti Siqueira has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Braga Figueiredo
Center for Research in Immuno-Oncology, Hospital Israelita Albert Einstein , São Paulo, São Paulo
1 shared publication - Ana Paula da Silva
Hospital Israelita Albert Einstein, São Paulo 05652-900, Brazil
1 shared publication - André Luis Lacerda Bachi
Post-Graduation Program in Health Sciences, Santo Amaro University (UNISA), São Paulo, Brazil
1 shared publication - Carlos Eduardo dos Santos Ferreira
Hospital Israelita Albert Einstein
1 shared publication - Carolina Nunes França
Post Graduation Program in Health Sciences, Santo Amaro University (UNISA), São Paulo 04829-300, Brazil
1 shared publication - Cristóvão Luis Pitangueira Mangueira
Clinical Laboratory, Hospital Israelita Albert Einstein, São Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
Cellular and Humoral Immune Responses to Vaccination for COVID-19 Are Negatively Impacted by Senescent T Cells: A Case Report
Background: Herein, we aimed to follow up on the cellular and humoral immune responses of a group of individuals who initially received the CoronaVac vaccine, followed by a booster with the Pfizer vaccine. Methods: Blood samples were collected: before and 30 days after the first CoronaVac dose; 30, 90, and 180 days after the second CoronaVac dose, and also 20 days after the booster with the Pfizer vaccine. Results: Whilst the positivity to gamma interferon-type cellular response increased after the first CoronaVac dose, neutralizing and IgG antibody levels only raised 30 days after the second dose, followed by a drop in these responses after 90 and 180 days. The booster with the Pfizer vaccine elicited a robust cellular and humoral response. A higher number of double-negative and senescent T cells, as well as increased pro-inflammatory cytokines levels were found in the participants with lower humoral immune responses. Conclusion: CoronaVac elicited an early cellular response, followed by a humoral response, which dropped 90 days after the second dose. The booster with the Pfizer vaccine significantly enhanced these responses. Furthermore, a pro-inflammatory systemic status was found in volunteers who presented senescent T cells, which could putatively impair the immune response to vaccination.
Open AccessCellular and Humoral Immune Responses to Vaccination for COVID-19 Are Negatively Impacted by Senescent T Cells: A Case Report
Background: Herein, we aimed to follow up on the cellular and humoral immune responses of a group of individuals who initially received the CoronaVac vaccine, followed by a booster with the Pfizer vaccine. Methods: Blood samples were collected: before and 30 days after the first CoronaVac dose; 30, 90, and 180 days after the second CoronaVac dose, and also 20 days after the booster with the Pfizer vaccine. Results: Whilst the positivity to gamma interferon-type cellular response increased after the first CoronaVac dose, neutralizing and IgG antibody levels only raised 30 days after the second dose, followed by a drop in these responses after 90 and 180 days. The booster with the Pfizer vaccine elicited a robust cellular and humoral response. A higher number of double-negative and senescent T cells, as well as increased pro-inflammatory cytokines levels were found in the participants with lower humoral immune responses. Conclusion: CoronaVac elicited an early cellular response, followed by a humoral response, which dropped 90 days after the second dose. The booster with the Pfizer vaccine significantly enhanced these responses. Furthermore, a pro-inflammatory systemic status was found in volunteers who presented senescent T cells, which could putatively impair the immune response to vaccination.